Gilead Sciences’ Kite Pharma unit is closing on approval of its second European approval for a CAR-T for cancer, after the CHMP backed its KTE-X19 therapy for mantle cell lymphoma.
There’s been a slew of scientific data coming from the American Society for Hematology (ASH) conference, but promising early data from Roche’s mosunetuzumab proved to be one of the major ta
Celgene has added another new indication for its blood cancer blockbuster Revlimid, with the FDA approving its use alongside Roche’s Rituxan for two additional forms of indolent non-Hodgkin
